Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Dermatologic 2Gastrointestinal 1Breast 1

Conditions

Melanoma 2Pancreatic Neoplasms 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 58Ipilimumab 53Cyclophosphamide 53Nivolumab 45aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 19dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11spartalizumab 10Filgrastim 10Dacarbazine 10cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × 1-methyltryptophan × Dermatologic × Clear all
NCT03301636 2022-09-27

NLG2107

Lumos Pharma

Phase 2 Terminated
21 enrolled 11 charts
Dermatologic

Melanoma

NCT00739609 2020-05-28

D-1MT

Lumos Pharma

Phase 1 Terminated
17 enrolled
BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡